Dirk De Ruysscher1, Angela van Baardwijk2, Rinus Wanders2, Lizza E Hendriks3, Bart Reymen2, Wouter van Empt2, Michel C Öllers2, Gerben Bootsma4, Cordula Pitz5, Linda van Eijsden6, Anne-Marie C Dingemans3. 1. Maastricht University Medical Center, Department of Radiation Oncology (Maastro Clinic), GROW School for Oncology and Developmental Biology, Maastricht, The Netherlands. Electronic address: dirk.deruysscher@maastro.nl. 2. Maastricht University Medical Center, Department of Radiation Oncology (Maastro Clinic), GROW School for Oncology and Developmental Biology, Maastricht, The Netherlands. 3. Maastricht University Medical Center, Department of Pulmonology, GROW School for Oncology and Developmental Biology, Maastricht, The Netherlands. 4. Zuyderland Hospital, Department of Pulmonology, Geleen, The Netherlands. 5. Laurentius Hospital, Department of Pulmonology, Roermond, The Netherlands. 6. Sint Jans Gasthuis, Department of Pulmonology, Weert, The Netherlands.
Abstract
BACKGROUND: Stage III non-small cell lung cancer (NSCLC) still has a poor prognosis. Prior studies with individualized, accelerated, isotoxic dose escalation (INDAR) with 3D-CRT showed promising results, especially in patients not treated with concurrent chemo-radiotherapy. We investigated if INDAR delivered with IMRT would improve the overall survival (OS) of stage III NSCLC patients treated with concurrent chemotherapy and radiotherapy. PATIENTS AND METHODS: Patients eligible for concurrent chemo-radiotherapy were entered in this prospective study. Radiotherapy was given to a dose of 45 Gy/30 fractions BID (1.5 Gy/fraction), followed by QD fractions of 2 Gy until a total dose determined by the normal tissue constraints. The primary endpoint was OS, secondary endpoints were loco-regional relapses and toxicity. RESULTS: From May 4, 2009 until April 26, 2012, 185 patients were included. The mean tumor dose was 66.0 ± 12.8 Gy (36-73 Gy), delivered in a mean of 39.7 fractions in an overall treatment time of 38.2 days. The mean lung dose (MLD) was 17.3 Gy. The median OS was 19.8 months (95% CI 17.3-22.3) with a 5-year OS of 24.3%. Loco-regional failures as first site of recurrence occurred in 59/185 patients (31.8%). Isolated nodal failures (INF) were observed in 3/185 patients (1.6%). Dyspnea grade 3 was seen in 3.2% of patients and transient dysphagia grade 3 in 22%. CONCLUSIONS: INDAR with IMRT concurrently with chemotherapy did not lead to a sign of an improved OS in unselected stage III NSCLC patients.
BACKGROUND: Stage III non-small cell lung cancer (NSCLC) still has a poor prognosis. Prior studies with individualized, accelerated, isotoxic dose escalation (INDAR) with 3D-CRT showed promising results, especially in patients not treated with concurrent chemo-radiotherapy. We investigated if INDAR delivered with IMRT would improve the overall survival (OS) of stage III NSCLCpatients treated with concurrent chemotherapy and radiotherapy. PATIENTS AND METHODS: Patients eligible for concurrent chemo-radiotherapy were entered in this prospective study. Radiotherapy was given to a dose of 45 Gy/30 fractions BID (1.5 Gy/fraction), followed by QD fractions of 2 Gy until a total dose determined by the normal tissue constraints. The primary endpoint was OS, secondary endpoints were loco-regional relapses and toxicity. RESULTS: From May 4, 2009 until April 26, 2012, 185 patients were included. The mean tumor dose was 66.0 ± 12.8 Gy (36-73 Gy), delivered in a mean of 39.7 fractions in an overall treatment time of 38.2 days. The mean lung dose (MLD) was 17.3 Gy. The median OS was 19.8 months (95% CI 17.3-22.3) with a 5-year OS of 24.3%. Loco-regional failures as first site of recurrence occurred in 59/185 patients (31.8%). Isolated nodal failures (INF) were observed in 3/185 patients (1.6%). Dyspnea grade 3 was seen in 3.2% of patients and transient dysphagia grade 3 in 22%. CONCLUSIONS:INDAR with IMRT concurrently with chemotherapy did not lead to a sign of an improved OS in unselected stage III NSCLCpatients.
Authors: Noëlle van der Voort van Zyp; Masoma Hashimzadah; Erik Kouwenhoven; Carmen Liskamp; Christa Gadellaa-van Hooijdonk; Ellen Pouw; Jose Belderbos; Klaartje Maas; Paul van de Vaart; Mirjam Mast Journal: Clin Transl Radiat Oncol Date: 2022-07-07
Authors: John D Fenwick; David B Landau; Angela T Baker; Andrew T Bates; Chinnamani Eswar; Angel Garcia-Alonso; Susan V Harden; Marianne C Illsley; Virginia Laurence; Zafar Malik; William Philip M Mayles; Elizabeth Miles; Nazia Mohammed; James Spicer; Paula Wells; Sindu Vivekanandan; Anne-Marie Mullin; Laura Hughes; Laura Farrelly; Yenting Ngai; Nicholas Counsell Journal: Int J Radiat Oncol Biol Phys Date: 2019-12-03 Impact factor: 7.038
Authors: Kate Haslett; Neil Bayman; Kevin Franks; Nicki Groom; Susan V Harden; Catherine Harris; Gerard Hanna; Stephen Harrow; Matthew Hatton; Paula McCloskey; Fiona McDonald; W David Ryder; Corinne Faivre-Finn Journal: Int J Radiat Oncol Biol Phys Date: 2020-11-21 Impact factor: 7.038
Authors: Huei-Tyng Huang; Michael G Nix; Douglas H Brand; David Cobben; Crispin T Hiley; John D Fenwick; Maria A Hawkins Journal: Cancers (Basel) Date: 2022-10-05 Impact factor: 6.575